326 related articles for article (PubMed ID: 11945149)
21. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
Yasumaru M; Tsuji S; Tsujii M; Irie T; Komori M; Kimura A; Nishida T; Kakiuchi Y; Kawai N; Murata H; Horimoto M; Sasaki Y; Hayashi N; Kawano S; Hori M
Cancer Res; 2003 Oct; 63(20):6726-34. PubMed ID: 14583467
[TBL] [Abstract][Full Text] [Related]
22. The role of cyclooxygenase inhibitors in cancer prevention.
Anderson WF; Umar A; Viner JL; Hawk ET
Curr Pharm Des; 2002; 8(12):1035-62. PubMed ID: 11945150
[TBL] [Abstract][Full Text] [Related]
23. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis.
Sengupta S; Sellers LA; Cindrova T; Skepper J; Gherardi E; Sasisekharan R; Fan TP
Cancer Res; 2003 Dec; 63(23):8351-9. PubMed ID: 14678996
[TBL] [Abstract][Full Text] [Related]
24. Use of NSAIDs for the chemoprevention of colorectal cancer.
Herendeen JM; Lindley C
Ann Pharmacother; 2003 Nov; 37(11):1664-74. PubMed ID: 14565811
[TBL] [Abstract][Full Text] [Related]
25. Dual acting anti-inflammatory drugs: a reappraisal.
Bertolini A; Ottani A; Sandrini M
Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
[TBL] [Abstract][Full Text] [Related]
26. Cyclooxygenase-2 inhibitors in tumorigenesis (part I).
Taketo MM
J Natl Cancer Inst; 1998 Oct; 90(20):1529-36. PubMed ID: 9790545
[TBL] [Abstract][Full Text] [Related]
27. Role of cyclooxygenase-2 in the development and treatment of oesophageal adenocarcinoma.
Buskens CJ; Ristimäki A; Offerhaus GJ; Richel DJ; van Lanschot JJ
Scand J Gastroenterol Suppl; 2003; (239):87-93. PubMed ID: 14743889
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.
Yao M; Kargman S; Lam EC; Kelly CR; Zheng Y; Luk P; Kwong E; Evans JF; Wolfe MM
Cancer Res; 2003 Feb; 63(3):586-92. PubMed ID: 12566300
[TBL] [Abstract][Full Text] [Related]
29. [COX and study of cancer therapy].
Yamada N; Ohira M; Hirakawa K
Gan To Kagaku Ryoho; 2004 Aug; 31(8):1147-51. PubMed ID: 15332534
[TBL] [Abstract][Full Text] [Related]
30. Chemoprevention strategies using NSAIDs and COX-2 inhibitors.
Keller JJ; Giardiello FM
Cancer Biol Ther; 2003; 2(4 Suppl 1):S140-9. PubMed ID: 14508092
[TBL] [Abstract][Full Text] [Related]
31. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
[TBL] [Abstract][Full Text] [Related]
32. Rofecoxib (Vioxx), a specific cyclooxygenase-2 inhibitor, is chemopreventive in a mouse model of colon cancer.
Evans JF
Am J Clin Oncol; 2003 Aug; 26(4):S62-5. PubMed ID: 12902858
[TBL] [Abstract][Full Text] [Related]
33. Enhanced cyclooxygenase-2 expression in sporadic and familial adenomatous polyposis of the human colon.
Khan KN; Masferrer JL; Woerner BM; Soslow R; Koki AT
Scand J Gastroenterol; 2001 Aug; 36(8):865-9. PubMed ID: 11495083
[TBL] [Abstract][Full Text] [Related]
34. COX-2, NSAIDs and human neoplasia. Part I: Colorectal neoplasms.
Nasir A; Fernandez PM; Chughtai OR; Kaiser HE
In Vivo; 2002; 16(6):501-9. PubMed ID: 12494894
[TBL] [Abstract][Full Text] [Related]
35. Suppression of intestinal polyp development by nimesulide, a selective cyclooxygenase-2 inhibitor, in Min mice.
Nakatsugi S; Fukutake M; Takahashi M; Fukuda K; Isoi T; Taniguchi Y; Sugimura T; Wakabayashi K
Jpn J Cancer Res; 1997 Dec; 88(12):1117-20. PubMed ID: 9473726
[TBL] [Abstract][Full Text] [Related]
36. COX-2: a target for prevention and treatment of esophageal cancer.
Altorki N
J Surg Res; 2004 Mar; 117(1):114-20. PubMed ID: 15013721
[No Abstract] [Full Text] [Related]
37. Cyclooxygenase inhibition in cancer prevention and treatment.
Anderson WF; Umar A; Hawk ET
Expert Opin Pharmacother; 2003 Dec; 4(12):2193-204. PubMed ID: 14640918
[TBL] [Abstract][Full Text] [Related]
38. Cyclooxygenase-2 and gastrointestinal cancer.
Mann JR; DuBois RN
Cancer J; 2004; 10(3):145-52. PubMed ID: 15285921
[TBL] [Abstract][Full Text] [Related]
39. A cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug enhances the growth inhibitory effect of butyrate in colorectal carcinoma cells expressing COX-2 protein: regulation of COX-2 by butyrate.
Crew TE; Elder DJ; Paraskeva C
Carcinogenesis; 2000 Jan; 21(1):69-77. PubMed ID: 10607736
[TBL] [Abstract][Full Text] [Related]
40. Growth regulation of Gardner's syndrome colorectal cancer cells by NSAIDs.
Hughes-Fulford M; Boman B
Adv Exp Med Biol; 1997; 407():433-41. PubMed ID: 9321987
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
